Shares of TG Therapeutics (NASDAQ: TGTX) plummeted 13.45% in pre-market trading on Monday after the biopharmaceutical company reported mixed second-quarter 2025 results and raised its revenue guidance. Despite the increased outlook, investors appeared to focus on the earnings miss and potential growth concerns.

TG Therapeutics reported Q2 earnings per share of $0.17, falling short of analyst estimates of $0.21. Revenue for the quarter came in at $141.1 million, also missing the consensus forecast of $146.4 million. However, this still represented a significant 92% year-over-year increase, driven by strong sales of its multiple sclerosis drug BRIUMVI.

In a positive development, the company raised its full-year 2025 BRIUMVI U.S. net revenue target to $570-$575 million, up from its previous guidance of $560 million. TG Therapeutics also increased its total global revenue target to approximately $585 million for the full year 2025, compared to the prior guidance of $575 million.

Despite the raised guidance, investors seem to be concerned about the company's ability to meet increasingly high expectations and maintain its growth trajectory. The sharp stock decline suggests that the market had anticipated even stronger results or more optimistic forecasts from TG Therapeutics. Additionally, the earnings miss may have raised questions about the company's profitability and cost management as it continues to scale its operations.